- Home
- HRMY
as 03-28-2025 4:00pm EST
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | PLYMOUTH MEETING |
| Market Cap: | 2.0B | IPO Year: | 2020 |
| Target Price: | $54.00 | AVG Volume (30 days): | 670.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 2.51 | EPS Growth: | 17.84 |
| 52 Week Low/High: | $28.14 - $41.61 | Next Earning Date: | 04-29-2025 |
| Revenue: | $714,734,000 | Revenue Growth: | 22.80% |
| Revenue Growth (this year): | 20.92% | Revenue Growth (next year): | 18.83% |
Stock Insider Trading Activity of Harmony Biosciences Holdings Inc. (HRMY)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Mar 3 '25 | Sell | $32.92 | 4,869 | $159,089.50 | 0 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Jan 24 '25 | Sell | $37.61 | 14,754 | $551,575.01 | 0 | |
| Kapadia Sandip | HRMY | CHIEF FINANCIAL OFFICER | Jan 24 '25 | Sell | $38.05 | 1,775 | $67,547.27 | 0 | |
| Dayno Jeffrey M. | HRMY | PRESIDENT, CEO | Jan 21 '25 | Sell | $40.13 | 19,293 | $774,245.45 | 0 | |
| Kapadia Sandip | HRMY | CHIEF FINANCIAL OFFICER | Jan 21 '25 | Sell | $40.18 | 25,000 | $1,004,597.50 | 0 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Jan 16 '25 | Sell | $38.71 | 30,598 | $1,147,715.34 | 0 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Jan 15 '25 | Sell | $37.01 | 10,507 | $388,840.95 | 0 | |
| Dierks Jeffrey | HRMY | CHIEF COMMERCIAL OFFICER | Jan 13 '25 | Sell | $37.04 | 7,180 | $265,946.48 | 0 |
Latest Harmony Biosciences Holdings Inc. News
HRMY Breaking Stock News: Dive into HRMY Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Is Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) the Best Small Cap Stock to Buy Before They Explode?
Business Wire
3 days ago
Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference
Argus Research
4 days ago
HRMY: Lowering target price to $43.00
Business Wire
5 days ago
Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands
Zacks
10 days ago
HRMY Down 10.8% in Six Months: How Should You Play the Stock?
MT Newswires
12 days ago
Mizuho Adjusts PT on Harmony Biosciences Holdings to $44 From $42, Maintains Outperform Rating
Insider Monkey
22 days ago
Harmony Biosciences Holdings, Inc. (HRMY): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts
Argus Research
25 days ago
HRMY: Rating increased to a BUY
Compare HRMY vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "HRMY Harmony Biosciences Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.